Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $6.56.
Several equities analysts have recently commented on AKYA shares. Morgan Stanley lowered shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $4.00 to $3.00 in a research report on Tuesday, August 6th. Piper Sandler decreased their target price on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Craig Hallum decreased their target price on shares of Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. BTIG Research lowered shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered shares of Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th.
View Our Latest Report on Akoya Biosciences
Institutional Investors Weigh In On Akoya Biosciences
Akoya Biosciences Stock Down 4.7 %
Akoya Biosciences stock opened at $2.87 on Wednesday. The company has a 50-day simple moving average of $2.70 and a 200-day simple moving average of $2.77. The firm has a market capitalization of $141.74 million, a P/E ratio of -1.95 and a beta of 1.36. The company has a debt-to-equity ratio of 3.43, a quick ratio of 1.98 and a current ratio of 2.73. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31.
Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). The business had revenue of $23.16 million during the quarter, compared to analyst estimates of $23.61 million. Akoya Biosciences had a negative net margin of 64.74% and a negative return on equity of 126.38%. During the same quarter in the prior year, the firm earned ($0.51) earnings per share. As a group, equities analysts expect that Akoya Biosciences will post -0.98 earnings per share for the current year.
About Akoya Biosciences
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Further Reading
- Five stocks we like better than Akoya Biosciences
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Small Caps With Big Return Potential
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.